Ergothioneine: The 'Longevity Vitamin' With a Chicken-and-Egg Problem

Written by the Nuvirox Research Team

Short answer: the biology is unusually persuasive and the human evidence is almost entirely correlational. Ergothioneine is a sulfur-containing amino acid derivative made only by certain fungi and bacteria. Humans cannot synthesise it, obtain it entirely from diet, and yet possess a specific transporter that actively concentrates it in tissue — a combination that usually signals something is worth keeping. Blood levels fall with age, and lower levels track with cognitive decline, frailty, and mortality in cohort after cohort. What is missing is the part that would make it actionable: a randomised trial showing that raising your levels changes anything.

Why the dedicated transporter argument is compelling

Evolution is not generous with transport proteins. Building and maintaining a high-affinity carrier for a molecule you cannot produce yourself is metabolically expensive, and it is the kind of thing organisms tend to do only for compounds that matter. Ergothioneine is absorbed via OCTN1 — organic cation transporter novel type 1 — which is expressed in the intestinal tract and in many tissues including the brain, and which concentrates ergothioneine intracellularly rather than simply allowing it to diffuse in.

Chemically, ergothioneine has a property that distinguishes it from most dietary antioxidants. At physiological pH it exists predominantly in the thione form rather than the thiol form, which confers unusual stability and resistance to autoxidation. Practically, that means it does not readily become a pro-oxidant the way some antioxidants can, and it persists in the body far longer than most — with a half-life measured in weeks rather than hours.

This is a genuinely different profile from the antioxidants covered in our piece on whether oxidative stress actually makes you tired, most of which are rapidly cleared and none of which have a dedicated transporter.

Ergothioneine's route into human tissue. The dedicated transporter step is what makes researchers take it seriously as a conditionally essential nutrient.

What human studies actually show

Low plasma ergothioneine predicted cognitive and functional decline in a memory clinic cohort. Wu and colleagues followed elderly participants attending memory clinics and found that lower plasma ergothioneine was associated with poorer baseline cognitive performance and with faster rates of decline in function and in multiple cognitive domains — memory, executive function, attention, visuomotor speed, and language. This is one of the more careful studies in the field, and its own limitations section is the most useful part.

The same group found associations with brain pathology. A separate study reported that low plasma ergothioneine levels were associated with neurodegeneration and cerebrovascular disease in dementia. In cognitively normal participants, lower baseline levels correlated with faster cognitive decline and brain pathology on follow-up over as long as five years.

Metabolomics work identified ergothioneine independently. Teruya and colleagues performed whole-blood metabolomics on dementia patients and found classes of disease-linked metabolites, with declining ergothioneine among them. A separate metabolomic analysis linked declining ergothioneine to frailty and cognitive impairment. When a compound emerges from an untargeted analysis rather than a hypothesis-driven one, that is a stronger signal than a study designed to find it.

Dietary intake associations point the same direction. Feng and colleagues conducted a community-based cross-sectional study in Singapore and found an association between mushroom consumption and lower prevalence of mild cognitive impairment. Beelman and colleagues framed the broader case in a 2020 paper asking whether ergothioneine is a 'longevity vitamin' limited in the American diet, noting substantial variation in national dietary intake.

The interventional evidence is thin, early, and partly unpublished. A 2025 review in Proceedings of the Nutrition Society concluded that interventional trials in older adults suggest ergothioneine supplementation may improve cognition, memory, and sleep quality and stabilise neurodegeneration biomarkers, with no safety concerns at doses up to 25 mg/day. That is an encouraging summary, and it rests on a small number of pilot studies. One frequently cited four-month trial in older adults with subjective memory complaints was sponsored by an ingredient manufacturer and announced by press release before publication.

Sorting the ergothioneine literature into what the data supports and what remains extrapolation.

The chicken-and-egg problem, stated plainly

The researchers who produced the strongest observational findings are explicit about the limitation, and it is worth quoting the logic. It remains unclear whether the observed low ergothioneine levels are a pathogenic factor leading to inadequate oxidative defence, or a consequence of antioxidant depletion driven by disease-associated oxidative stress. And if it is the former, it is still not clear whether the decline reflects reduced transporter efficiency, changed diet, or something else.

This is not a nitpick. If ergothioneine falls because a neurodegenerative process is consuming it, then topping it up is treating a gauge rather than an engine. The same problem has appeared repeatedly in nutrition research — low vitamin D in inflammatory illness being the best-known example. Only a randomised trial with a clinical endpoint can separate the two, and that trial has not been run at adequate size or duration.

What ergothioneine won't do

It will not treat or prevent dementia; nothing in the published evidence supports that, and any product implying it is making a claim well beyond the data. It will not produce a felt effect — the outcomes in this literature are cognitive test scores and biomarkers measured over months, not sensations. And it will not compensate for the modifiable risk factors that actually dominate cognitive aging: blood pressure control, hearing loss management, physical activity, sleep quality, and smoking cessation all have far stronger evidence.

If you are experiencing memory problems that concern you or that others have noticed, that warrants a clinical assessment. Cognitive symptoms have treatable causes — thyroid disease, B12 deficiency, sleep apnoea, depression, medication effects — and a supplement is not the appropriate first step.

If you want more ergothioneine, where does it come from?

Mushrooms are by far the richest dietary source, with concentrations varying substantially by species — oyster, shiitake, maitake, and king oyster generally contain considerably more than white button mushrooms. Ergothioneine is heat-stable, so cooking does not destroy it. Smaller amounts appear in beans, oat bran, and organ meats, largely reflecting soil fungi and bacteria in the food chain.

Supplement doses in the interventional literature have been modest — the safety statement in the 2025 review referenced doses up to 25 mg per day, which is well within what a regular mushroom eater might obtain from food. That is an unusual situation for a longevity compound, and it is a point in ergothioneine's favour: the studied dose is achievable through diet. For a different mushroom-derived compound with a similarly modest evidence base, see our assessment of lion's mane for brain fog. And for another mechanism where laboratory chemistry outruns human data, our piece on glycation and aging covers similar ground.

Frequently asked questions

Can I get enough ergothioneine from food?

Probably, if you eat mushrooms regularly. Intake varies widely across countries, and the doses used in the small interventional studies are within reach of a mushroom-containing diet. Whether higher intake than that produces additional benefit has not been tested.

Can I test my ergothioneine level?

Plasma ergothioneine can be measured, but it is a research assay rather than a routine clinical test, and there is no validated reference range or action threshold. A number without an interpretation is of limited use.

Is ergothioneine safe?

It has an unusually clean profile so far. It is a normal dietary constituent, it is not readily pro-oxidant, and the interventional studies reported no safety concerns at doses up to 25 mg/day. Long-term supplementation at higher doses has not been studied.

Why isn't it classified as a vitamin?

Because the formal definition requires demonstrating a deficiency state with defined clinical consequences, and nobody has established that for ergothioneine. Beelman and colleagues proposed the 'longevity vitamin' framing precisely because it sits in an unusual category — not essential in the classical sense, but plausibly beneficial at higher intakes.

Does it interact with anything?

No clinically significant interactions have been documented, which partly reflects how little it has been studied in people taking medication. OCTN1 also transports some drugs, which raises a theoretical competition question that has not been examined in practice.

From Nuvirox

Why we formulated NAD+ Restore

Ergothioneine and NAD+ are both examples of molecules where cellular supply falls with age — but NAD+ has something ergothioneine does not: precursors with published human pharmacokinetic and clinical trial data. NAD+ Restore delivers 500 mg of nicotinamide riboside, within the dose range used in those trials, with a 60-day money-back guarantee.

• 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
• 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
• 10 mg galactomannans from fenugreek — to support absorption.
• 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.

Learn more about NAD+ Restore →

The bottom line

Ergothioneine has the most interesting biological argument of any compound in this category. A molecule humans cannot make, obtain only from diet, and actively concentrate in tissue through a dedicated transporter is not an accident. The observational data are consistent across independent cohorts and emerged partly from untargeted metabolomics rather than motivated searching. What is missing is causal evidence, and the field's own reviewers say so directly: nobody knows whether low ergothioneine drives decline or reflects it. Eating more mushrooms is a low-cost, low-risk response to a genuinely interesting hypothesis. Building a supplement protocol around it is running ahead of what has been demonstrated.

References

1. Wu LY, Kan CN, Cheah IK, et al. Low plasma ergothioneine predicts cognitive and functional decline in an elderly cohort attending memory clinics. Antioxidants (Basel). 2022;11(9):1717. PMID: 36139790. DOI: 10.3390/antiox11091717. PMCID: PMC9495818.
2. Wu LY, Cheah IK, Chong JR, et al. Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radic Biol Med. 2021;177:201–211. PMID: 34673145. DOI: 10.1016/j.freeradbiomed.2021.10.019.
3. Teruya T, Chen YJ, Kondoh H, Fukuji Y, Yanagida M. Whole-blood metabolomics of dementia patients reveal classes of disease-linked metabolites. Proc Natl Acad Sci U S A. 2021;118(37):e2022857118. PMID: 34493657. DOI: 10.1073/pnas.2022857118.
4. Beelman RB, Kalaras MD, Phillips AT, Richie JP. Is ergothioneine a 'longevity vitamin' limited in the American diet? J Nutr Sci. 2020;9:e52.
5. Ergothioneine for cognitive health, longevity and healthy ageing: where are we now? Proc Nutr Soc. 2025. PMID: 40968729.
6. Feng L, Cheah IKM, Ng MMX, et al. The association between mushroom consumption and mild cognitive impairment: a community-based cross-sectional study in Singapore. J Alzheimers Dis. 2019;68(1):197–203.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.